Assessment of the systemic distribution of a bioconjugated anti-Her2 magnetic nanoparticle in a breast cancer model by means of magnetic resonance imaging
Source abstract
Abstract
The aim of this study was to determine the systemic distribution of magnetic nanoparticles of 100 nm diameter (MNPs) coupled to a specific monoclonal antibody anti-Her2 in an experimental breast cancer (BC) model. The study was performed in two groups of Sprague–Dawley rats: control (n = 6) and BC chemically induced (n = 3). Bioconjugated “anti-Her2-MNPs” were intravenously administered, and magnetic resonance imaging (MRI) monitored its systemic distribution at seven times after administration. Non-heme iron presence associated with the location of the bioconjugated anti-Her2-MNPs in splenic, hepatic, cardiac and tumor tissues was detected by Perl’s Prussian blue (PPB) stain. Optical density measurements were used to semiquantitatively determine the iron presence in tissues on the basis of a grayscale values integration of T1 and T2 MRI sequence images. The results indicated a delayed systemic distribution of MNPs in cancer compared to healthy conditions with a maximum concentration of MNPs in cancer tissue at 24 h post-infusion.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Glycosylation and Glycoproteins Research · Nanoparticle-Based Drug Delivery · Monoclonal and Polyclonal Antibodies Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (28)
Show source-provided references
1. Abramson V, Arteaga CL (2011) New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available. Clin Cancer Res 17:952–95810.1158/1078-0432.CCR-09-1947 ↗
2. Brannon-Peppas L, Blanchette JO (2004) Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 56:1649–165910.1016/j.addr.2004.02.014 ↗
3. CHEMICELL at http// www.Chemicell.com . 1st Nov 2015
4. Daldrup-Link HE, Golovko D, Ruffell B, Denardo CR, Ansari C et al (2011) MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin Cancer Res 17(17):5695–570410.1158/1078-0432.CCR-10-3420 ↗
5. DeNardo SJ, DeNardo G, Miers LA, Natarajan A, Foreman AR, Gruettner C et al (2005) Development of tumor targeting bioprobes (111In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy. Clin Cancer Res 11(19 Pt 2):7087s–7092s10.1158/1078-0432.CCR-1004-0022 ↗
6. Duncan R, Gaspar R (2011) Nanomedicine(s) under the microscope. Mol Pharm 8(6):2101–214110.1021/mp200394t ↗
7. Giustini JA, Ivkov R, Hoopes JP (2011) Magnetic nanoparticle biodistribution following intratumoral administration. Nanotechnology 22(34):34510110.1088/0957-4484/22/34/345101 ↗
8. Giustini JA, Petryk AA, Hoopes JP (2012) Ionizing radiation increases systemic nanoparticle tumor accumulation. Nanomedicine 8(6):818–82110.1016/j.nano.2012.05.001 ↗
9. Huang HS, Hainfeld JF (2013) Intravenous magnetic nanoparticle cancer hyperthermia. Int J Nanomed 8:2521–2532
10. Ilinskaya AN, Dobrovolskaia MA (2013) Nanoparticles and the blood coagulation system. Nanomedicine 8(5):773–78410.2217/nnm.13.48 ↗
11. Khosravi Shahi P, Pérez Manga G (2006) La relevancia clínica de la sobreexpresión de HER-2 en el cáncer de mama. An Med Interna (Madrid) 23(3):103–10410.4321/S0212-71992006000300001 ↗
12. Kirpotin DB, Drummond DC, Shao Y, Shalaby R, Hong K, Nielsen UB et al (2006) Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 66(13):6732–674010.1158/0008-5472.CAN-05-4199 ↗
13. Kreb DL, Looij BG, Ernst MF, Rutten MJCM, Jager GJ, der Linden Van et al (2013) Ultrasound-guided radiofrequency ablation of early breast cancer in resection specimen. Lesson for further research. Breast 22(4):543–54710.1016/j.breast.2012.11.004 ↗
14. Laurent S, Mahmoudi M (2011) Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of cancer. Int J Mol Epidemiol Genet 2(4):367–390
15. Manenti G, Bolacchi F, Perretta T, Cossu E, Pistolese CA, Buonomo OC et al (2009) Small breast cancers: in vivo percutaneous US-guided radiofrequency ablation with dedicated cool-tip radiofrequency system. Radiology 251(2):339–34610.1148/radiol.2512080905 ↗
16. Manenti G, Scarano AL, Pistolese CA, Perretta T, Bonanno E, Orlandi A et al (2013) Subclinical breast cancer: minimally invasive approaches. our experience with percutaneous radiofrequency ablation vs. cryotherapy. Breast Care 8(5):356–36010.1159/000355707 ↗
17. Silva JG, Sánchez V, Polo SM, González CA (2013a) Expression of c-erbB-2 in breast cancer cell lines as experimental receptor of magnetic nanoparticles. In: Conference proceedings IEEE engineering in medicine and biology society, July, Osaka, pp 4498–450110.1109/EMBC.2013.6610546 ↗
18. Silva JG, Maldonado J, Tapia JS, Herrera NE, Polo SM, Martínez SG, González CA (2013b) Selective targeting of breast cancer cells MCF-7 by ferromagnetic nanoparticles. In: Proceedings of the V latin American congress on biomedical engineering CLAIB 2011, IFMBE proceedings, vol 33, pp 983–98610.1007/978-3-642-21198-0_250 ↗
19. Silva JG, López J, Sánchez V, Lozano L, Gonzalez C (2015) Breast cancer tissue marked selectively by magnetic nanoparticles in an experimental animal model. J Nanoasci Nanotechnol 15:1–6 (ISSN: 1533-4880)10.1166/jnn.2015.9731 ↗
20. Silva-Escobedo JG, Sánchez-Monroy V, Rojas-Lopez M, Lopez-Cruz J, Gonzalez CA (2014) C-erbB-2 as a possible target for the use of magnetic nanoparticles in breast cancer cells. IEEE Trans Nanobiosci 13(3):300–30710.1109/TNB.2014.2319316 ↗
21. Slamon DJ, Clark GM, Wong SG, Levine WJ, Ullrich A, Human MWL (1987) Breast cancer. Correlation of relapse and survival with amplification of the HER-2/neuoncogene. Science 235:177–18210.1126/science.3798106 ↗
22. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–71210.1126/science.2470152 ↗
23. Storm G, Belliot SO, Daemen T, Lasic DD (1995) Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 17:31–4810.1016/0169-409X(95)00039-A ↗
24. Thompson JH, Adlakha H (1991) Dose-responsive induction of mammary gland carcinomas by the intraperitoneal injection of 1-methyl-l-nitrosourea. Cancer Res 51:3411–3415
25. Tsuchiya K, Nitta N, Sonoda A, Nitta-Seko A, Ohta S, Otani H et al (2011) Histological study of the biodynamics of iron oxide nanoparticles with different diameters. Int J Nanomed 6:1587–159410.2147/IJN.S22189 ↗
26. Wang J, Chen Y, Chen B, Ding J, Xia G, Gao C et al (2010) Pharmacokinetic parameters and tissue distribution of magnetic Fe3O4 nanoparticles in mice. Int J Nanomed 5:861–866
27. Weissleder R, Stark DD, Engelstad BL, Bacon BA, Compton CC, White DL et al (1989) Superparamagnetic iron oxide: pharmacokinetics and toxicity. Am J Roentgenol 152:167–17310.2214/ajr.152.1.167 ↗
28. Yoshinaga Y, Enomoto Y, Fujimitsu R, Shimakura M, Nabeshima K, Iwasaki A (2013) Image and pathological changes after radiofrequency ablation of invasive breast cancer: a pilot study of nonsurgical therapy of early breast cancer. World J Surg 37(2):356–36310.1007/s00268-012-1820-9 ↗